EMERYVILLE, Calif., April 12, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, presented a poster on the efficacy of its Aganocide compound as a potential agent for prevention and treatment for urinary catheter blockage and encrustation, often leading to urinary tract infections, at the 2011 conference of The Simon Foundation for Continence held in Chicago on April 12-13.
